Menu
Innovative medicines through next generation targeted delivery.
Clinical stage versatile platform for disease prevention and therapeutics.

About us.

Founded in Singapore in 2013, ACM Biolabs is a biotechnology company that is using its proprietary thermostable polymer-based nanoparticle delivery platform to develop new formulations for use in multiple therapeutic fields. 

We are based in two world leading innovation hubs for biotechnology: Singapore and Switzerland. To support our clinical operations, we recently opened a new facility in Sydney, Australia.

Why we do it

We want to change the status quo of lipid-based targeted delivery of various drug payloads which is limiting its broader therapeutic applications.

How we do it

We are pioneering next next-generation polymer-based delivery technology platform that is able to deliver multiple drug payloads by targeting specific tissues or cells and potentially overcome well-known challenges faced by lipid nanoparticle-based products. Artificial cell membranes (or “ACMs”) are the building blocks of our patented technology. These ACMs are composed of block co-polymers to create nano delivery carriers. We have spent over 15 years perfecting and patenting scalable process for creating these modular delivery platform for various payloads. 

What we do

ACM Biolabs’ Tunable Platform (ATP™) is a polymer/lipid hybrid, non-viral delivery platform that offers the flexibility to deliver multiple payloads including oligonucleotides, small molecules, proteins, and mRNA. ATP™ is thermostable, allowing mRNA storage at 4°C in contrast to the current lipid nanoparticle-based delivery systems that require ultra-low cold storage. ACM Biolabs has programs targeting multiple organs, tissues, and immune cells. 

The Team.

Show only:
Madhavan Nallani
details
Madhavan Nallani
Founder | Chief Executive Officer | Chief Scientific Officer
Chairman of the Board ACM Biolabs & ACM Biosciences
Business Development

Developed the core intellectual property of the company while working in Germany, the Netherlands and Singapore (at the Institute of Materials Research & Engineering (IMRE, A*STAR) and also at Nanyang Technological University).

Pierre Vandepapelière
details
Pierre Vandepapelière
Clinical Advisor

Pharmacologist. Vaccines Expert with more than 30 years of experience of R&D.
Doctorat at the Université catholique de Louvain, Belgium. Leading function at GSK, Abivax, NeoVacs, Imcyse, and Amyl Therapeutics. CEO at Vaccibio Consulting.

Erich Erber
details
Erich Erber
Director of the Board ACM Biolabs

Founder of the Erber Group, an Austrian animal nutrition company (now part of DSM), which consists of more than 50 affiliates in all continents. He is also founder of the SAN Pacific Investments Group. Recipient of numerous awards including the Austrian Export award and Ernst & Young Entrepreneur of the Year and is an Honorary Senator of the University of Veterinary Medicine and the University of Natural Resources and Applied Life Sciences, Vienna.

Erich is the key investor representative on ACM Biolabs’ Board of Directors.

Sang Bin Ong
details
Sang Bin Ong
Director of the Board ACM Biolabs

Sang Bin is currently the managing director of Ritz Venture Capital, a Singapore based family fund that focuses in supporting early-stage companies. He has over 30 years of experience in venture investments as well as mentorship within the academic community. With his background in engineering and business, he is a strong supporter of applying cutting edge technology and cultivating talents to address some of the key challenges in the world in the near future.

Dennis Klinman
details
Dennis Klinman
Scientific Advisor
Onur Boyman
details
Onur Boyman
Clinical Immunologist, Scientific Advisor

Professor & Chair, Clinical Immunology, University of Zurich, Director, Department of Immunology, University Hospital Zurich.

Peter Moran
details
Peter Moran
Corporate Affairs

PhD. Managed the Micro- and Nano-systems group of 50 R&D staff in the Singapore research institute where the polymersome technology originated. Thereafter, co-founded Singular ID, a successful tech start-up which received funding from institutional investors based in the US, Europe and Asia and was acquired by a multinational. Has worked with Dr Nallani on ACM since 2011.

Katherine Schultheis
details
Katherine Schultheis
Head of Discovery Research

Katherine Schultheis joined ACM Biosciences in 2022 as Head of Discovery Research with a strong background of preclinical development of DNA based vaccines and immunotherapeutics. Katherine has more than 10 years of academic and corporate research experience in the fields of infectious diseases, autoimmunity and oncology. She was heading a research team at Inovio Pharmaceuticals in San Diego, California, before moving back to the greater Basel area in 2021. Katherine obtained her Master’s level degree in Biochemistry from University of Potsdam, Germany.

Qiwei Fong
details
Qiwei Fong
Accountant

Before joining ACM Biolabs, Qiwei was an audit manager with experience in SMEs and subsidiaries of MNCs of various industries. He is also a member of the Institute of Singapore Chartered Accountants and CPA Australia.

Melvin Liew
details
Melvin Liew

Prior to joining ACM Biolabs, Melvin received his PhD in Materials Science and Engineering from Nanyang Technological University in 2023. His PhD research focused on the fabrication and characterization of biomimetic nanoparticles for drug and RNA delivery.

Shaoqiong Liu
details
Shaoqiong Liu
Principal Scientist

Dr. Liu received her PhD in chemical and biomolecular engineering from National University of Singapore (NUS). She has more than 15 years of research and development experience in Biomedical science and Bioengineering. She has generated 5 patents and 42 papers in reputable journals including Nature communications and Advanced Materials.

Jian Hang Lam
details
Jian Hang Lam
Senior Scientist

Jian Hang Lam holds a Ph.D. from the Yong Loo Lin School of Medicine, National University of Singapore. He was trained in pre-clinical dengue vaccine development and gained experience in virology and immunology, with special focus on investigating correlates of protection.

Ser Yue Loo
details
Ser Yue Loo
Senior Scientist

Ser Yue Loo is a Senior Scientist at ACM Biolabs. Prior to joining ACM Biolabs, Ser Yue carried out her postdoctoral fellowship at Genome Institute of Singapore, where she conducted research on therapeutics for treatment of triple negative breast cancer. Her work led to the successful translation from bench to bedside with the initiation of a clinical trial BEXMET in National Cancer Centre Singapore.
Loo Ser Yue obtained her PhD from Yong Loo Lin School of Medicine at National University of Singapore in 2014.

Gaurav Sinsinbar
details
Gaurav Sinsinbar
Senior Scientist

Gaurav joined ACM Biolabs in 2021, after completing his PhD research in the field of point-of-care diagnostics from the School of Material Science and Engineering at NTU.

Yan Jun Lee
details
Yan Jun Lee
Scientist

Yan Jun Lee is a Scientist at ACM Biolabs. She obtained her PhD from Nanyang Technological University, Singapore in 2021. She then carried out her postdoctoral fellowship at National University of Singapore. She has conducted neuroscience studies in molecular and system settings throughout her academics training.

Anivind Kaur Bindra
details
Anivind Kaur Bindra
Scientist

Anivind Kaur Bindra is a Scientist at ACM Biolabs. She obtained bachelor’s and master’s degrees in Chemistry from University of Delhi, India in 2015. Thereafter, from her research internship at Defence Research and Development Organization, India, she got interested into the cancer drug delivery field. She further pursued Ph.D. in Chemistry from Nanyang Technological University, Singapore in 2021. During Ph.D. and Postdoctoral training, her research interests included the design and development of functional organic-inorganic hybrid nanomaterials for nanomedicine.

Teck Wan Chia
details
Teck Wan Chia
Senior Research Assistant

Senior research associate at ACM Biolabs. Obtained a bachelor’s degree in Chemistry and Biological Chemistry in 2019 at the Nanyang Technological University.

Wei Xiang Poh
details
Wei Xiang Poh
Research Assistant

Research Assistant at ACM Biolabs. Obtained a diploma in Chemical Engineering in 2015 and Bachelor’s Degree in Chemistry and Biological Chemistry in 2021 at Nanyang Technological University.

Eunice Yoong Eng Chia
details
Eunice Yoong Eng Chia
Research Assistant

Research Assistant at ACM Biolabs. Obtained a diploma in Medicinal Chemistry in 2017 and a degree of Bachelor of Science in Chemistry and Biological Chemistry in 2021 at Nanyang Technological University.”

Jing Yi Fong
details
Jing Yi Fong
Research Assistant

Fong Jing Yi is a Research Assistant at ACM Biolabs. She obtained a diploma in Pharmaceutical Science and a degree in Pharmaceutical Engineering, focusing in Biologics where she performed her 8 months internship at ACM Biolabs, working on accessing the stability of formulations at different storage conditions and durations.

view more

We are looking for highly motivated specialists – take a look at our career offers

Our Focus.

ATPTM stands for ACM Biolabs Tunable Platform.

Technology Platform

Artificial cell membranes (or “ACMs”) are the building blocks of our patented technology. These ACMs are composed of block co-polymers to create nano delivery carriers. We have spent over 15 years perfecting and patenting scalable process for creating these modular delivery platform for various payloads. 

Our data show that ATPs can deliver multiple payloads including oligonucleotides, small molecules, proteins, and mRNA. ATP™ is thermostable, allowing mRNA storage at 4°C in contrast to the current lipid nanoparticle-based delivery systems that require ultra-low cold storage. ATP™ has the potential to transform targeted delivery of various drug payloads.

Potential to revolutionize the therapeutic delivery to cells and tissues.

Therapeutic Approach

At ACM Biolabs, we are developing innovative medicines using our targeted ATP™ delivery platform. Our non-viral, ATP™-based nanocarriers are suitable for diverse drug payloads with various routes of administration, including mucosal delivery. 

ATP™ can target the right tissues and cells. This powerful toolbox has the potential to address a broad range of diseases. 
Our first clinical program is ongoing, and we are working on additional indications to demonstrate the ability to deliver multiple modalities.

Vaccines

Phase 1 completed. Polymersomes formulated with spike protein co- administered with polymersomes formulated CpG 7909, as a Covid booster vaccine. 

Oncology

IND ready polymersomes with CpG combined with anti-PD1 in lung cancer patients as targeted immuno therapy. 

Preclinical evaluation of broader innate agonist and lung targeted chemotherapy. 

Ophthalmology

Preclinical evaluation of polymersomes with monoclonal antibodies suitable for topical application to the retina.

Achievements in graphics.

A growing pipeline comprising the targeted delivery of proteins, monoclonal antibodies, oligonucleotides, and small molecules.

At ACM Biolabs we are driven to change the status quo of limited therapeutic applications offered by lipid-based delivery. We are developing diverse treatments with multiple drug modalities with our modular ATPTM platform. 

 
Discovery
Lead
Optimization
Clinical
Development
Ind
Enabling
Clinical
Development Ph I
Milestones
Infectious Disease
ACM-001
SARS-CoV-2 Beta variant vaccine
Q4 | 2023
Final data*
Oncology
ACM-005
CpG 7909
HSA IND
approval**
Q4 | 2023
Oncology
ACM-005++
Combination CpG 7909 + TLR7/8
Candidate
selection
Q1 | 2024
Oncology
ACM-008
Lung Targeting Chemotherapy
Candidate
selection
Q1 | 2024
Ophthalmology
ACM-007
Retinal disorders
PoC
Q4 | 2023

* Platform Clinical Validation
** IIT with National Cancer Center Singapore  (NCCS)

Documented achievements.

News.

Contact.

bd@acmbiolabs.com

Contact us for any questions regarding business development.

office@acmbiosciences.com

Contact us for any questions regarding science, studies or general office matters.

ACM Biolabs Pte Ltd

71 Nanyang Drive, #02M-02 NTU Innovation Centre, Singapore 638075
Phone: +65 6265 5646

ACM Biolabs Pty Ltd

139 Macquarie Street
Sydney NSW 2000
Australia

ACM Biosciences AG

Aeschenplatz 6
4052 Basel
Switzerland

Career Opportunities

We are currently building a high quality and motivated team to develop our polymer-based delivery technology and bring innovative medicines to patients with high unmet medical need. Working at the intersection of pre-clinical and clinical research as a part of multidisciplinary team We we are looking for candidates with expertise in mRNA technologies, nano-technology, chemistry of lipids- and polymer-based delivery formulations and analytical methods. Interested applicants should please forward their resumé / CV to career@acmbiolabs.com

Career Opportunities